effectiveness Serum Give Pfizer The BioNTech in preventing infection by Corona Virus It decreased from 88% to 47% six months after the second dose, according to data published on Monday that was evaluated by health agencies in the Arab Republic of Egypt. United State When deciding on the need for stimulant doses.
The data, published in the medical journal The Lancet, was released earlier in August, ahead of peer review.
The analysis shows that the vaccine’s effectiveness in preventing hospitalization and death remains high, at 90%, for at least six months, even against the highly contagious delta variant of the coronavirus.
The data suggest that the decrease in the prevention of symptomatic cases is due to decreased efficacy rather than infectious variants, the researchers said.
Scientists at Pfizer and health care provider Kaiser Permanente studied the health records of nearly 3.4 million people who were members of Kaiser Permanente in Southern California between December 2020 when the vaccine first became available and in August 2021.
“Our variant analysis clearly shows that the vaccine (Pfizer/BioNTech) is effective against all variants, including Delta,” said Louis Godard, senior vice president and medical director of Pfizer’s Vaccine Division.
Vaccine efficacy against the delta variant was 93% after the first month, and decreased to 53% after four months. Against other coronavirus variants, efficacy decreased from 97% to 67%.
“Gamers. Unfortunate Twitter teachers. Zombie pioneers. Internet fans. Hardcore thinkers.”